

Advanced Gastric Carcinoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/AC373D48D09CEN.html>

Date: September 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: AC373D48D09CEN

Abstracts

This report can be delivered to the clients within 3-5 business days

DelveInsight's, "Advanced Gastric Carcinoma - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Advanced Gastric Carcinoma Understanding

Advanced Gastric Carcinoma: Overview

Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to. The most common symptoms of stomach cancer include: unexplained weight loss, feeling and being sick, stomach pain, difficulty swallowing, feeling tired. Advanced stage means your stomach cancer has spread. External radiotherapy can help to control your cancer and reduce symptoms. Treatments such as chemotherapy or radiotherapy or targeted drugs can sometimes help to reduce symptoms. Other treatments such as laser therapy or stents can treat a

blockage in the stomach. Surgery can help relieve symptoms of advanced stomach cancer if your cancer is causing a blockage. Laser therapy uses hot beams of light to burn away cancer cells. This can help control symptoms of advanced stomach cancer.

'Advanced Gastric Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Gastric Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Gastric Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Gastric Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Gastric Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Gastric Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Gastric Carcinoma.

Advanced Gastric Carcinoma Emerging Drugs Chapters

This segment of the Advanced Gastric Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Gastric Carcinoma Emerging Drugs

Camrelizumab: Jiangsu Hengrui Medicine

Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a

humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.

Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

Further product details are provided in the report.

Advanced Gastric Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Gastric Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Gastric Carcinoma

There are approx. 50+ key companies which are developing the therapies for Advanced Gastric Carcinoma. The companies which have their Advanced Gastric Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Gastric Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Gastric Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Gastric Carcinoma drugs.

Advanced Gastric Carcinoma Report Insights

Advanced Gastric Carcinoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Advanced Gastric Carcinoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Advanced Gastric Carcinoma drugs?

How many Advanced Gastric Carcinoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Gastric Carcinoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Gastric Carcinoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Advanced Gastric Carcinoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Jiangsu Hengrui Medicine

BeiGene

CSPC ZhongQi Pharmaceutical Technology

LintonPharm Co.,Ltd.

Bristol-Myers Squibb

Hanmi Pharmaceutical

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Idience Co., Ltd.

Shanghai Henlius Biotech

AstraZeneca

Nanjing Legend Biotech Co.

ALX Oncology Inc.

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Genentech

Innovent Biologics (Suzhou) Co. Ltd.

Qilu Pharmaceutical Co., Ltd.

NextCure, Inc.

Chengdu Kanghong Biotech Co., Ltd.

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Janssen Pharmaceutical K.K.

Shanghai Miracogen Inc.

Ambrx, Inc.

Imugene Limited

Vedanta Biosciences, Inc.

Celon Pharma SA

Bicycle Tx Limited

Seagen Inc.

Key Products

Camrelizumab

Pamiparib

Mitoxantrone Hydrochloride Liposome

Catumaxomab

Ipilimumab

Relatlimab

FLX475

DP303c

IDX-1197

HLX22

Olaparib

LCAR-C18S

ALX148

KN026

Atezolizumab

Sintilimab

QL1604

NC410

KH903

GQ1001

Amivantamab

IMU-131

BT8009

VE800

CPL304110

ARX788

MRG002

SEA-TGT

Contents

Introduction

Executive Summary

Advanced Gastric Carcinoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Advanced Gastric Carcinoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Late Stage Products (Phase III)

Comparative Analysis

Camrelizumab: Jiangsu Hengrui Medicine

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

Pamiparib: BeiGene

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

Venadaparib: Idience

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.

Inactive Products
Comparative Analysis
Advanced Gastric Carcinoma Key Companies
Advanced Gastric Carcinoma Key Products
Advanced Gastric Carcinoma- Unmet Needs
Advanced Gastric Carcinoma- Market Drivers and Barriers
Advanced Gastric Carcinoma- Future Perspectives and Conclusion
Advanced Gastric Carcinoma Analyst Views
Advanced Gastric Carcinoma Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Advanced Gastric Carcinoma
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Advanced Gastric Carcinoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Advanced Gastric Carcinoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/AC373D48D09CEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC373D48D09CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970